Amgen's (AMGN) potential Sjogren's disease treatment dazodalibep has met its primary endpoint of demonstrating statistically significant reductions in systemic disease activity compared with placebo in a late-stage trial, the company said Wednesday.
Sjogren's disease is a chronic autoimmune condition causing dry eyes and a dry mouth and potentially impacting other organs.
Both the 1,500 milligram every four-week and the 3,000 milligram every 12-week regiments of dazodalibep showed reductions in disease activity, the company said.
Patients treated with the drug showed greater increases in saliva flow, and oral dryness, compared with placebo, the company said.
Serious adverse events and discontinuations due to adverse events were "balanced" across three treatment groups, the company said.
Shares of the company were down more than 1% in recent Wednesday premarket activity.
Comments